[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100426218":3},{"organization":4,"armGroups":7,"interventions":49,"overallOfficials":56,"centralContacts":60,"locations":67,"responsibleParty":226,"collaborators":55,"id":228,"slug":55,"hasResults":229,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":55,"eligibilityCriteria":233,"healthyVolunteers":229,"sex":234,"minAge":235,"maxAge":55,"enrollmentInfo":236,"targetDuration":55,"studyType":239,"phases":240,"briefSummary":242,"conditions":243,"keywords":252,"overallStatus":70,"whyStopped":55,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8,14,18,22,26,30,34,37,40,43,46],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a Dose Escalation","EXPERIMENTAL","Multiple dose levels of NX-2127 to be evaluated; determination of MTD\u002FPhase 1b recommended dose",[13],"Drug: NX-2127",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b Dose Optimization Stage 1 in CLL or SLL (Dose A)","CLL\u002FSLL patients whose disease has failed treatment with a BTK inhibitor",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase 1b Dose Optimization Stage 1 in MCL (Dose A)","MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Phase 1b Dose Optimization Stage 1 in FL, MZL or WM (Dose A)","FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Phase 1b Dose Optimization Stage 1 in DLBCL (Dose A)","DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another\u002Fpalliative regimen",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Phase 1b Dose Optimization Stage 1 in PCNSL (Dose A)","PCNSL patients whose disease has failed at least 1 prior line of treatment",[13],{"label":35,"type":10,"description":16,"interventionNames":36},"Phase 1b Dose Optimization Stage 2 in CLL or SLL (Randomized to Dose A or Dose B)",[13],{"label":38,"type":10,"description":20,"interventionNames":39},"Phase 1b Dose Optimization Stage 2 in MCL (Randomized to Dose A or Dose B)",[13],{"label":41,"type":10,"description":24,"interventionNames":42},"Phase 1b Dose Optimization Stage 2 in FL, MZL or WM (Randomized to Dose A or Dose B)",[13],{"label":44,"type":10,"description":28,"interventionNames":45},"Phase 1b Dose Optimization Stage 2 in DLBCL (Randomized to Dose A or Dose B)",[13],{"label":47,"type":10,"description":32,"interventionNames":48},"Phase 1b Dose Optimization Stage 2 in PCNSL (Randomized to Dose A or Dose B)",[13],[50],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"DRUG","NX-2127","Oral NX-2127",[9,15,27,23,19,31,35,44,41,38,47],null,[57],{"name":58,"affiliation":5,"role":59},"Study Director","STUDY_DIRECTOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":65,"email":66},"Patient Outreach","CONTACT","(415)-230-7806","7806","nx2127001@nurixtx.com",[68,81,91,100,110,120,129,139,149,158,168,177,187,197,206,216],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":55},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":76,"coordinates":77},"Point",[78,79],-117.97729,34.13945,{"lat":79,"lon":78},{"facility":82,"status":83,"city":84,"state":72,"zip":85,"country":74,"cosmosGeoPoint":86,"geoPoint":90,"contacts":55},"University of California Irvine","COMPLETED","Orange","92868",{"type":76,"coordinates":87},[88,89],-117.85311,33.78779,{"lat":89,"lon":88},{"facility":92,"status":83,"city":93,"state":72,"zip":94,"country":74,"cosmosGeoPoint":95,"geoPoint":99,"contacts":55},"University of California San Francisco Medical Center","San Francisco","94143",{"type":76,"coordinates":96},[97,98],-122.41942,37.77493,{"lat":98,"lon":97},{"facility":101,"status":70,"city":102,"state":103,"zip":104,"country":74,"cosmosGeoPoint":105,"geoPoint":109,"contacts":55},"Sarah Cannon Research Institute at Colorado Blood Cancer Institute","Denver","Colorado","80218",{"type":76,"coordinates":106},[107,108],-104.9847,39.73915,{"lat":108,"lon":107},{"facility":111,"status":83,"city":112,"state":113,"zip":114,"country":74,"cosmosGeoPoint":115,"geoPoint":119,"contacts":55},"Mount Sinai Comprehensive Cancer Center","Miami Beach","Florida","33140",{"type":76,"coordinates":116},[117,118],-80.13005,25.79065,{"lat":118,"lon":117},{"facility":121,"status":83,"city":122,"state":113,"zip":123,"country":74,"cosmosGeoPoint":124,"geoPoint":128,"contacts":55},"Sarah Cannon Research Institute at Florida Cancer Specialists","Sarasota","34203",{"type":76,"coordinates":125},[126,127],-82.53065,27.33643,{"lat":127,"lon":126},{"facility":130,"status":70,"city":131,"state":132,"zip":133,"country":74,"cosmosGeoPoint":134,"geoPoint":138,"contacts":55},"The University of Chicago Medical Center","Chicago","Illinois","60637",{"type":76,"coordinates":135},[136,137],-87.65005,41.85003,{"lat":137,"lon":136},{"facility":140,"status":70,"city":141,"state":142,"zip":143,"country":74,"cosmosGeoPoint":144,"geoPoint":148,"contacts":55},"National Institutes of Health Clinical Center","Bethesda","Maryland","20814",{"type":76,"coordinates":145},[146,147],-77.10026,38.98067,{"lat":147,"lon":146},{"facility":150,"status":83,"city":151,"state":151,"zip":152,"country":74,"cosmosGeoPoint":153,"geoPoint":157,"contacts":55},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":76,"coordinates":154},[155,156],-74.00597,40.71427,{"lat":156,"lon":155},{"facility":159,"status":83,"city":160,"state":161,"zip":162,"country":74,"cosmosGeoPoint":163,"geoPoint":167,"contacts":55},"University of Cincinnati Medical Center","Cincinnati","Ohio","45267",{"type":76,"coordinates":164},[165,166],-84.51439,39.12711,{"lat":166,"lon":165},{"facility":169,"status":83,"city":170,"state":161,"zip":171,"country":74,"cosmosGeoPoint":172,"geoPoint":176,"contacts":55},"OSU Wexner Medical Center","Columbus","43210",{"type":76,"coordinates":173},[174,175],-82.99879,39.96118,{"lat":175,"lon":174},{"facility":178,"status":70,"city":179,"state":180,"zip":181,"country":74,"cosmosGeoPoint":182,"geoPoint":186,"contacts":55},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":76,"coordinates":183},[184,185],-86.78444,36.16589,{"lat":185,"lon":184},{"facility":188,"status":83,"city":189,"state":190,"zip":191,"country":74,"cosmosGeoPoint":192,"geoPoint":196,"contacts":55},"Baylor University Medical Center","Dallas","Texas","75246",{"type":76,"coordinates":193},[194,195],-96.80667,32.78306,{"lat":195,"lon":194},{"facility":198,"status":70,"city":199,"state":190,"zip":200,"country":74,"cosmosGeoPoint":201,"geoPoint":205,"contacts":55},"MD Anderson Cancer Center","Houston","77030",{"type":76,"coordinates":202},[203,204],-95.36327,29.76328,{"lat":204,"lon":203},{"facility":207,"status":70,"city":208,"state":209,"zip":210,"country":74,"cosmosGeoPoint":211,"geoPoint":215,"contacts":55},"Huntsman Cancer Institute, University of Utah","Salt Lake City","Utah","84112",{"type":76,"coordinates":212},[213,214],-111.89105,40.76078,{"lat":214,"lon":213},{"facility":217,"status":83,"city":218,"state":219,"zip":220,"country":74,"cosmosGeoPoint":221,"geoPoint":225,"contacts":55},"Swedish Cancer Institute","Seattle","Washington","98104",{"type":76,"coordinates":222},[223,224],-122.33207,47.60621,{"lat":224,"lon":223},{"type":227,"investigatorFullName":55,"investigatorTitle":55,"investigatorAffiliation":55,"oldNameTitle":55,"oldOrganization":55},"SPONSOR","100426218",false,"NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Patients must have measurable disease per disease-specific response criteria\n* Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)\n* Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)\n* Adequate organ and bone marrow function\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol\n\nInclusion Criteria for Patients in Phase 1a:\n\n* Have histologically confirmed R\u002FR CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL\n* Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit\n* Must require systemic therapy\n\nInclusion Criteria for Patients in Phase 1b:\n\n* Must have one of the following histologically documented R\u002FR B-cell malignancies:\n\n  * CLL\u002FSLL whose disease has failed treatment with a BTKi;\n  * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen\n  * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi\n  * PCNSL whose disease failed at least 1 prior line of treatment\n  * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another\u002F palliative regimen (either progressed post stem cell transplant or transplant-ineligible)\n\nExclusion Criteria:\n\n* Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of known\u002Fsuspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)\n* Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug\n* Bleeding diathesis, or other known risk for acute blood loss\n* Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug\n* Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)\n* Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).\n* Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible\n* Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active liver disease from any cause\n* Active viral reactivation (e.g., CMV or EBV)\n* Use of systemic corticosteroids exceeding 20 mg\u002Fday prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg\u002Fday prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.\n* Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study\n* Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug\n* Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days","ALL","18 Years",{"count":237,"type":238},248,"ESTIMATED","INTERVENTIONAL",[241],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.",[244,245,246,247,248,249,250,251],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Waldenstrom Macroglobulinemia (WM)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Follicular Lymphoma (FL)","Diffuse Large B-cell Lymphoma (DLBCL)","Primary Central Nervous System Lymphoma (PCNSL)",[253,254,255,256,257,258,259,260,52,261,262,263,264],"BTK Degrader","BTK Inhibitor","B-cell Malignancy","Lymphoma","IMiD","Lenalidomide","Pomalidomide","Bruton's Tyrosine Kinase","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","C481","C481S","2026-03-18",{"date":267,"type":268},"2026-03-20","ACTUAL",{"date":270,"type":268},"2021-05-05",{"date":272,"type":238},"2027-05",{"name":5,"class":6},16]